PRQR_OUT_1 [2025-04-24 05:57:47 -0400] 5116 Bytes | 1418 tokens | Cum: 1418 tkns (17.72% of 8k)
==========================================================================

Alright, let’s light it up, because it's 5:57 AM on Thu Apr 24, 2025, and I'm charging into ProQR Therapeutics N.V. (PRQR), popping from $1.32 to $1.37. Is this our star stock of the day, or just a quick blip on the radar? I've got the scoop—time to analyze!

--- COMPANY PROFILE ---
Company: ProQR Therapeutics N.V. (PRQR)
IPO: 2014-09-18 (10 Years Ago)
Market Cap: $92,278,307
Shares Outstanding: 80,820,000
Exchange: XNAS
Description: ProQR Therapeutics NV is a biopharmaceuticals company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.

Here’s a list of headlines for ProQR Therapeutics N.V.:

Apr-15-25 09:01AM - Strength Seen in BioNTech (BNTX): Can Its 6.0% Jump Turn into More Strength?
Apr-14-25 07:00AM - ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth
Mar-13-25 07:00AM - ProQR Announces Year End 2024 Operating and Financial Results
Dec-12-24 07:16AM - ProQR Therapeutics announces $8.1M in new funding from RSRT
Dec-11-24 07:00AM - ProQR Therapeutics Announces $8.1 Million in New Funding from Rett Syndrome Research Trust to Expand RNA Editing Collaboration
Dec-10-24 08:00AM - ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist
Dec-06-24 06:47AM - ProQR Therapeutics price target raised to $8 from $5 at JMP Securities
Dec-05-24 08:00AM - ProQR Therapeutics to Host Virtual Analyst and Investor Event on December 11, 2024
Nov-08-24 07:26AM - ProQR Therapeutics sees cash runway into mid-2027
Nov-07-24 07:00AM - ProQR Announces Third Quarter 2024 Operating and Financial Results
Oct-25-24 04:45PM - ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement
Oct-22-24 10:15PM - ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement
Oct-22-24 10:15PM 04:01PM - ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares
Oct-07-24 08:00AM - ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society
Sep-10-24 04:30PM - ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference
Aug-08-24 07:00AM - ProQR Announces Second Quarter 2024 Operating and Financial Results
Jun-18-24 08:00AM - ProQR Announces Presentation on its Axiomer RNA Editing Technology at RNA Editing Summit
May-09-24 07:00AM - ProQR Announces First Quarter 2024 Operating and Financial Results
May-08-24 08:00AM - ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer RNA Editing Program Targeting NTCP for Cholestatic Diseases
Apr-23-24 07:00AM - ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024
Apr-22-24 04:31PM - ProQR Highlights Upcoming Presentations on Axiomer RNA Editing at ASGCT 27th Annual Meeting
Apr-19-24 07:00AM - ProQR Achieves Successful Defense of New Challenge to its Axiomer IP Portfolio

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2025-03-13T11:00:00Z - ProQR Announces Year End 2024 Operating and Financial Results
B2 - 2024-12-10T13:00:00Z - ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist
B3 - 2024-10-25T20:45:00Z - ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement
B4 - 2024-10-23T02:15:00Z - ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement
B5 - 2024-10-07T12:00:00Z - ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society
B6 - 2024-06-25T08:32:00Z - Regenxbio (RGNX) Soars 6.4%: Is Further Upside Left in the Stock?

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for ProQR Therapeutics N.V. (PRQR).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

PRQR_OUT_3 [2025-04-24 05:57:47 -0400] 904 Bytes | 250 tokens | Cum: 1670 tkns (20.88% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**ProQR Announces Year End 2024 Operating and Financial Results**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/03/13/3042018/33039/en/ProQR-Announces-Year-End-2024-Operating-and-Financial-Results.htmlProQR Therapeutics is advancing its Axiomer™ ADAR-mediated RNA editing pipeline, with plans to file a CTA for its lead program AX-0810 targeting NTCP for Cholestatic diseases in Q2 2025. The company expects up to four clinical data readouts in 2025 and 2026, and has a strong financial position with €149.4 million in cash and cash equivalents as of the end of 2024.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

PRQR_OUT_5 [2025-04-24 05:57:48 -0400] 940 Bytes | 285 tokens | Cum: 1957 tkns (24.46% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-22T08:24:03Z - ProQR Therapeutics (NASDAQ:PRQR) Sees Significant Decline in Short Interest...
A2 - 2025-04-22T08:06:09Z - Walleye Capital LLC Takes Position in ProQR Therapeutics (NASDAQ:PRQR)...
A3 - 2025-04-20T09:54:14Z - 575,000 Shares in ProQR Therapeutics (NASDAQ:PRQR) Bought by Altium Capital Management LLC...
A4 - 2025-04-17T11:52:46Z - 2,825,000 Shares in ProQR Therapeutics (NASDAQ:PRQR) Bought by Affinity Asset Advisors LLC...
A5 - 2025-04-17T06:12:08Z - ProQR Therapeutics (NASDAQ:PRQR) Given Average Rating of "Buy" by Brokerages...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

PRQR_OUT_7 [2025-04-24 05:57:48 -0400] 1181 Bytes | 330 tokens | Cum: 2289 tkns (28.61% of 8k)
==========================================================================

Showing A1 (chunk 1 of 5): A1:
**ProQR Therapeutics (NASDAQ:PRQR) Sees Significant Decline in Short Interest**Date: 2025-04-22Source: {'uri': 'marketbeat.com', 'dataType': 'news', 'title': 'Market Beat'}URL: https://www.marketbeat.com/instant-alerts/proqr-therapeutics-nasdaqprqr-sees-significant-decline-in-short-interest-2025-04-20/ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) was the target of a large decrease in short interest during the month of March. As of March 31st, there was short interest totalling 843,100 shares, a decrease of 17.3% from the March 15th total of 1,020,000 shares. Currently, 1.1% of the shares of the company are sold short. Based on an average trading volume of 476,600 shares, the short-interest ratio is currently 1.8 days.

Several hedge funds have recently modified their holdings of PRQR. Adage Capital Partners GP L.L.C. raised its holdings in shares of ProQR Therapeutics by 164.9%

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

PRQR_OUT_9 [2025-04-24 05:57:49 -0400] 1181 Bytes | 300 tokens | Cum: 2591 tkns (32.39% of 8k)
==========================================================================

Showing A1 (chunk 2 of 5): during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 9,602,280 shares of the biopharmaceutical company's stock valued at $25,446,000 after acquiring an additional 5,976,813 shares during the last quarter. Woodline Partners LP acquired a new position in ProQR Therapeutics in the 4th quarter valued at $9,426,000. Affinity Asset Advisors LLC purchased a new position in ProQR Therapeutics in the 4th quarter valued at $7,486,000. Millennium Management LLC boosted its stake in ProQR Therapeutics by 1,864.4% during the 4th quarter. Millennium Management LLC now owns 2,827,280 shares of the biopharmaceutical company's stock worth $7,492,000 after purchasing an additional 2,683,351 shares during the last quarter. Finally, Platinum Investment Management Ltd. purchased a new stake in shares of ProQR Therapeutics during the fourth quarter worth $4,076,000. Institutional investors and

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

PRQR_OUT_11 [2025-04-24 05:57:50 -0400] 1181 Bytes | 331 tokens | Cum: 2924 tkns (36.55% of 8k)
==========================================================================

Showing A1 (chunk 3 of 5): hedge funds own 32.65% of the company's stock.

PRQR opened at $1.14 on Friday. The firm's fifty day simple moving average is $1.74 and its two-hundred day simple moving average is $2.52. ProQR Therapeutics has a 52-week low of $1.07 and a 52-week high of $4.62. The company has a market cap of $119.94 million, a price-to-earnings ratio of -3.56 and a beta of 0.25.

Several equities research analysts have commented on the stock. Citigroup raised shares of ProQR Therapeutics from a "neutral" rating to a "buy" rating and set a $4.00 price target on the stock in a report on Monday, March 10th. Chardan Capital reiterated a "buy" rating and set a $4.00 price target on shares of ProQR Therapeutics in a research report on Friday, March 14th. Oppenheimer started coverage on shares of ProQR Therapeutics in a research note on Friday, January 10th. They set an "outperform" rating and a $15.00 price

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

PRQR_OUT_13 [2025-04-24 05:57:50 -0400] 1181 Bytes | 301 tokens | Cum: 3227 tkns (40.34% of 8k)
==========================================================================

Showing A1 (chunk 4 of 5): objective on the stock. Finally, HC Wainwright increased their price target on shares of ProQR Therapeutics from $10.00 to $12.00 and gave the stock a "buy" rating in a report on Friday, March 14th. One investment analyst has rated the stock with a sell rating, five have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $9.50.

Check Out Our Latest Analysis on ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GAL

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

PRQR_OUT_15 [2025-04-24 05:57:51 -0400] 1172 Bytes | 250 tokens | Cum: 3479 tkns (43.49% of 8k)
==========================================================================

Showing A1 (chunk 5 of 5): T1).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Before you consider ProQR Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ProQR Therapeutics wasn't on the list.

While ProQR Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

PRQR_OUT_17 [2025-04-24 05:57:52 -0400] 238 Bytes | 59 tokens | Cum: 3540 tkns (44.25% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

PRQR_OUT_19 [2025-04-24 05:57:59 -0400] 5061 Bytes | 1219 tokens | Cum: 4761 tkns (59.51% of 8k)
==========================================================================

This is our set of metrics for ProQR Therapeutics N.V..
Please analyze the numbers.

+---------------------+-----------------------+-------------------------+-------------------------+
| Volume: 622,769 | Perf Month: -12.12% | Option/Short: Yes / Yes | Sales Y/Y TTM: 190.40% |
+---------------------+-----------------------+-------------------------+-------------------------+
| Avg Volume: 513.53K | Perf Quarter: -35.12% | Short Float: 1.19% | ROE: -43.72% |
+---------------------+-----------------------+-------------------------+-------------------------+
| Rel Volume: 1.22 | Index: - | Short Ratio: 1.64 | ROI: -29.12% |
+---------------------+-----------------------+-------------------------+-------------------------+
| RSI (14): 52.75 | Market Cap: 152.56M | Short Interest: 0.84M | Sales Surprise: -11.08% |
+---------------------+-----------------------+-------------------------+-------------------------+
| ATR (14): 0.13 | Shs Outstand: 102.71M | Beta: 0.35 | EPS Surprise: -3.30% |
+---------------------+-----------------------+-------------------------+-------------------------+
| SMA20: 14.58% | Shs Float: 70.76M | Sales Q/Q: 30.09% | P/E: - |
+---------------------+-----------------------+-------------------------+-------------------------+
| SMA50: -16.87% | Inst Own: 42.77% | Sales past 5Y: 82.57% | Earnings: Mar 13 BMO |
+---------------------+-----------------------+-------------------------+-------------------------+
| SMA200: -37.50% | Insider Own: 32.74% | Employees: - | |
+---------------------+-----------------------+-------------------------+-------------------------+
| Perf Week: 21.85% | Insider Trans: 0.00% | Debt/Eq: 0.18 | |
+---------------------+-----------------------+-------------------------+-------------------------+

The next section covers any insider trading by ProQR Therapeutics N.V. officers or majority shareholders (if available).

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): N/A
Net Income: N/A
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 1.45
Average Volume: 631119.48
30-Day High: 1.61
30-Day Low: 1.12
No detailed financial data available.
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of ProQR Therapeutics N.V. (PRQR).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about ProQR Therapeutics N.V..

2) MARKET_SCORE[]
This conversation was initiated because PRQR is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for PRQR.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, PRQR could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect PRQR to increase 50% from its current price of $1.12, say: PRICE_TARGET[1.68]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of ProQR Therapeutics N.V..

11) ETHICAL_RATING[]
Rate ProQR Therapeutics N.V.’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of ProQR Therapeutics N.V..
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

PRQR_IN_21 [2025-04-24 05:57:59 -0400] 126 Bytes | 29 tokens | Cum: 5038 tkns (62.98% of 8k)
==========================================================================

====================================
[2025-04-24 05:57:59] # Analysis Completed
Elapsed Time: 13.47 seconds